In addition to proliferating cancer cells and various types of normal cells, such as those of
the bone marrow, conventional cytotoxic chemotherapeutics affect the endothelium of the …

The words 'side effect'usually evoke a mixture of fear and anxiety in cancer patients
receiving chemotherapy. But, as it turns out, not all side effects are necessarily harmful, or …

Purpose Over the past few years, more and more new selective molecules directed against
specific cellular targets have become available for cancer therapy, leading to impressive …

The administration of chemotherapy at reduced doses given at regular, frequent time
intervals, termed 'metronomic'chemotherapy, presents an alternative to standard maximal …

Tumor angiogenesis is recognized as a major therapeutic target in the fight against cancer.
The key involvement of angiogenesis in tumor growth and metastasis has started to redefine …

From previous preclinical findings continuous low dose (metronomic) chemotherapy is
thought to inhibit tumor angiogenesis. This suggests that activated endothelial cells may be …

Cancer chemotherapy utilized at maximum tolerated, toxic doses, rarely results in sustained
total tumor eradication, with patients ultimately failing a variety of chemotherapeutic …

Recent preclinical studies have shown that frequent administration in vivo of low doses of
chemotherapeutic drugs (“metronomic” dosing) can affect tumor endothelium and inhibit …

Tumour endothelium is a new target for anticancer treatments. Proliferating endothelial cells
from the tumour, even if qualitatively different from those of blood vessels in the normal …

Metronomic antiangiogenic chemotherapy, the prolonged administration of relatively low
drug doses, at close regular intervals with no significant breaks, has been mainly studied at …